AbCellera Biologics (ABCL) Cash & Current Investments (2020 - 2026)

AbCellera Biologics has reported Cash & Current Investments for 7 years, with the latest figure at $102.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 83.81% year-over-year to $102.1 million; the trailing twelve-month figure through Mar 2026 stood at $102.1 million (down 83.81% YoY), and the FY2025 full-year result was $558.8 million, down 14.11% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $102.1 million, down from $558.8 million in the prior quarter.
• The five-year high for Cash & Current Investments was $911.5 million in Q4 2022, with the low at $102.1 million in Q1 2026.
• Historically, Cash & Current Investments has averaged $506.1 million across 5 years, with a median of $558.8 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Current Investments surged 310.95% — and 2026, when it tumbled 83.81%.
• AbCellera Biologics' Cash & Current Investments stood at $911.5 million in 2022, then slumped by 82.63% to $158.3 million in 2023, then surged by 310.95% to $650.6 million in 2024, then dropped by 14.11% to $558.8 million in 2025, then slumped by 81.74% to $102.1 million in 2026.
• The last three Cash & Current Investments figures came in at $102.1 million (Q1 2026), $558.8 million (Q4 2025), and $520.7 million (Q3 2025), per Business Quant data.